Cargando…
Structure-Guided Evolution of Potent and Selective CHK1 Inhibitors through Scaffold Morphing
[Image: see text] Pyrazolopyridine inhibitors with low micromolar potency for CHK1 and good selectivity against CHK2 were previously identified by fragment-based screening. The optimization of the pyrazolopyridines to a series of potent and CHK1-selective isoquinolines demonstrates how fragment-grow...
Autores principales: | Reader, John C., Matthews, Thomas P., Klair, Suki, Cheung, Kwai-Ming J., Scanlon, Jane, Proisy, Nicolas, Addison, Glynn, Ellard, John, Piton, Nelly, Taylor, Suzanne, Cherry, Michael, Fisher, Martin, Boxall, Kathy, Burns, Samantha, Walton, Michael I., Westwood, Isaac M., Hayes, Angela, Eve, Paul, Valenti, Melanie, de Haven Brandon, Alexis, Box, Gary, van Montfort, Rob L. M., Williams, David H., Aherne, G. Wynne, Raynaud, Florence I., Eccles, Suzanne A., Garrett, Michelle D., Collins, Ian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2011
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3241339/ https://www.ncbi.nlm.nih.gov/pubmed/22111927 http://dx.doi.org/10.1021/jm2007326 |
Ejemplares similares
-
Discovery of 3-Alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles
as Selective, Orally Bioavailable CHK1 Inhibitors
por: Lainchbury, Michael, et al.
Publicado: (2012) -
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma
por: Walton, Mike I., et al.
Publicado: (2015) -
Discovery of 4-Amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides As Selective, Orally Active Inhibitors of Protein Kinase B (Akt)
por: McHardy, Tatiana, et al.
Publicado: (2010) -
Structure-Based Design of
Orally Bioavailable 1H-Pyrrolo[3,2-c]pyridine
Inhibitors of Mitotic Kinase Monopolar Spindle 1 (MPS1)
por: Naud, Sébastien, et al.
Publicado: (2013) -
Introduction of
a Methyl Group Curbs Metabolism of
Pyrido[3,4-d]pyrimidine Monopolar Spindle
1 (MPS1) Inhibitors and Enables the Discovery of the Phase 1 Clinical
Candidate N(2)-(2-Ethoxy-4-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl)-6-methyl-N(8)-neopentylpyrido[3,4-d]pyrimidine-2,8-diamine (BOS172722)
por: Woodward, Hannah L., et al.
Publicado: (2018)